Investor Alert

London Markets Close in:

press release

Feb. 28, 2022, 7:30 a.m. EST

Syros to Participate in Upcoming Virtual Investor Conferences in March

CAMBRIDGE, Mass., (BUSINESS WIRE) -- Syros Pharmaceuticals /zigman2/quotes/201168308/composite SYRS -2.88% , a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming virtual investor conferences in March. Management will also be available for one-on-one meetings. Details are as follows:

Cowen 42nd Annual Healthcare Conference Date: Monday, March 7
Panel Title: Novel Oncology Targets
Panel Time: 12:50 p.m. ET

Oppenheimer 32nd Annual Healthcare Conference Date: Wednesday, March 16
Presentation Time: 3:20 p.m. ET

To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com . An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARa agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter ( @SyrosPharma ) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005020/en/

SOURCE: Syros Pharmaceuticals

Media Contact:
Courtney Solberg
Syros Pharmaceuticals
917-698-9253
csolberg@syros.com Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

COMTEX_403230101/2456/2022-02-28T07:30:07

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2022

/zigman2/quotes/201168308/composite
US : U.S.: Nasdaq
$ 0.86
-0.03 -2.88%
Volume: 118,910
Aug. 19, 2022 11:06a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$55.87 million
Rev. per Employee
$203,565
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.